Format

Send to

Choose Destination
Mol Neurodegener. 2017 Nov 21;12(1):87. doi: 10.1186/s13024-017-0229-1.

A validated antibody panel for the characterization of tau post-translational modifications.

Author information

1
BioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
2
AbbVie GmbH&Co KG, Knollstraße 50, 67061, Ludwigshafen am Rhein, Germany.
3
Institute for Molecular and Cell Biology, Mannheim University of Applied Sciences, Paul-Wittsack-Straße 10, 68163, Mannheim, Germany.
4
German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Straße 27, 53127, Bonn, Germany.
5
BioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany. ehrnhoefer@bio.mx.

Abstract

BACKGROUND:

Tau is a microtubule-binding protein, which is subject to various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Aberrant PTMs such as hyperphosphorylation result in tau aggregation and the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease (AD). In order to study the importance of PTMs on tau function, antibodies raised against specific modification sites are widely used. However, quality control of these antibodies is lacking and their specificity for particular modifications is often unclear.

METHODS:

In this study, we first designed an online tool called 'TauPTM', which enables the visualization of PTMs and their interactions on human tau. Using TauPTM, we next searched for commercially available antibodies against tau PTMs and characterized their specificity by peptide array, immunoblotting, electrochemiluminescence ELISA and immunofluorescence technologies.

RESULTS:

We demonstrate that commercially available antibodies can show a significant lack of specificity, and PTM-specific antibodies in particular often recognize non-modified versions of the protein. In addition, detection may be hindered by other PTMs in close vicinity, complicating the interpretation of results. Finally, we compiled a panel of specific antibodies and show that they are useful to detect PTM-modified endogenous tau in hiPSC-derived neurons and mouse brains.

CONCLUSION:

This study has created a platform to reliably and robustly detect changes in localization and abundance of post-translationally modified tau in health and disease. A web-based version of TauPTM is fully available at http://www.tauptm.org .

KEYWORDS:

Alzheimer’s disease; Antibody validation; Post-translational modification; Tau

PMID:
29157277
PMCID:
PMC5697095
DOI:
10.1186/s13024-017-0229-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center